Fed’s Powell opens door to potential rate cuts at Jackson Hole
Friday, Citizens JMP analysts reiterated their Market Outperform rating on MacroGenics (NASDAQ:MGNX), focusing on the biopharmaceutical company’s ongoing developments. The stock, which has declined over 86% in the past year and is currently trading near its 52-week low of $2.03, remains a focus for analysts. The analysts highlighted their position on the sidelines due to the early stage of MacroGenics’ follow-on B7-H3 ADC MGC026 and other ADC programs. They also noted the absence of data on lorigerlimab in metastatic castration-resistant prostate cancer (mCRPC). According to InvestingPro analysis, the company appears undervalued at current levels, with 4 analysts recently revising their earnings estimates upward.
The analysts are anticipating an update on lorigerlimab, expected in the second half of 2025, which they believe will be a significant catalyst for MacroGenics’ stock in the near term. They emphasized that positive overall response rate (ORR) and radiographic progression-free survival (rPFS) results could indicate a potential opportunity in the treatment of mCRPC. While the Phase 2 trial is using an appropriate chemotherapy comparator arm, the analysts expressed caution pending the availability of data. Analyst targets currently range from $4 to $8 per share, reflecting significant potential upside from current levels.
The report also mentioned that Gilead Sciences (NASDAQ:GILD) could make a decision on whether to opt into a partnership in 2025, a move that Citizens JMP estimates could immediately drive value for MacroGenics.
Regarding the company’s financials, MacroGenics reported operating expenses of $260 million for the fiscal year, with a year-end cash balance of $202 million. According to the analysts, this cash reserve should provide MacroGenics with sufficient financial runway into the second half of 2026. InvestingPro data confirms the company’s strong liquidity position, with a current ratio of 3.75 and more cash than debt on its balance sheet. While the company maintains solid financial health metrics, investors should note it’s currently burning through cash rapidly. Get deeper insights into MacroGenics’ financial health and access 13 additional exclusive ProTips with an InvestingPro subscription.
In other recent news, MacroGenics Inc. reported its fourth-quarter 2024 earnings, revealing a better-than-expected loss per share of -0.07, compared to the anticipated -0.40. The company also reported a significant revenue increase to $49.4 million, surpassing the forecasted $29.19 million. For the full year, MacroGenics’ total revenue reached $150 million, a substantial rise from $58.7 million in 2023, primarily driven by collaborative agreements. Despite this revenue growth, the company reported a net loss of $67 million, attributed to heightened research and development expenses.
Analysts noted the company’s ongoing advancements in its clinical pipeline, with expectations for clinical updates in the second half of 2025. Additionally, MacroGenics’ cash balance was reported at $201.7 million as of December 31, 2024, projected to extend its cash runway into the second half of 2026. The company also highlighted its strategic focus on developing its antibody-based cancer treatments. In terms of analyst activity, there was no mention of upgrades or downgrades from firms such as Barclays (LON:BARC) or Leerink Partners. These developments reflect MacroGenics’ ongoing efforts to advance its clinical programs and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.